Shared REMS For Transmucosal Fentanyls Could Expand Market For Meda’s Onsolis As It Exits More Restrictive Program
This article was originally published in The Pink Sheet Daily
Class-wide Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products will begin operations in March 2012, with participants in REMS for individual products to be transitioned automatically to the new system.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
Participants in a two-day FDA meeting on REMS standardization and assessment suggested a website containing all REMS information and enrollment functions and allowing interaction with existing health records and claims systems would facilitate compliance with safety requirements.
Drug Safety and Risk Management Advisory Committee overwhelmingly favors elimination of paper-based sticker system to verify prescriber enrollment and documentation of safe use conditions under Prometheus’ REMS for the irritable bowel syndrome drug.